Browse EFR3B

Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor Cytoplasm, cytosol Note=Palmitoylation anchors the protein to the plasma membrane (PubMed:23229899, PubMed:25380825). A small amount is observed in the cytosol (PubMed:25380825).
Domain -
Function

Component of a complex required to localize phosphatidylinositol 4-kinase (PI4K) to the plasma membrane (PubMed:23229899, PubMed:25608530, PubMed:26571211). The complex acts as a regulator of phosphatidylinositol 4-phosphate (PtdIns(4)P) synthesis (Probable). In the complex, EFR3B probably acts as the membrane-anchoring component (PubMed:23229899). Also involved in responsiveness to G-protein-coupled receptors; it is however unclear whether this role is direct or indirect (PubMed:25380825).

> Gene Ontology
 
Biological Process GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0007009 plasma membrane organization
GO:0030258 lipid modification
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:1990778 protein localization to cell periphery
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EFR3B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EFR3B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EFR3B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7330.0334
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.820.486
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6720.444
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1450.686
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0150.99
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3020.857
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0360.933
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0510.971
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0030.998
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1430.692
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0950.856
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2640.0877
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EFR3B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.36.227.10.116
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EFR3B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EFR3B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EFR3B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EFR3B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EFR3B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EFR3B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEFR3B
NameEFR3 homolog B
Aliases FLJ37871; KIAA0953; EFR3 homolog B (S. cerevisiae); Protein EFR3 homolog B
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EFR3B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.